Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy.
Institute of Translational Pharmacology, National Research Council, CNR, Via del Fosso del Cavaliere 100, 00133 Rome, Italy.
Int J Mol Sci. 2021 Jul 12;22(14):7455. doi: 10.3390/ijms22147455.
Human DNA topoisomerase IB controls the topological state of supercoiled DNA through a complex catalytic cycle that consists of cleavage and religation reactions, allowing the progression of fundamental DNA metabolism. The catalytic steps of human DNA topoisomerase IB were analyzed in the presence of a drug, obtained by the open-access drug bank Medicines for Malaria Venture. The experiments indicate that the compound strongly and irreversibly inhibits the cleavage step of the enzyme reaction and reduces the cell viability of three different cancer cell lines. Molecular docking and molecular dynamics simulations suggest that the drug binds to the human DNA topoisomerase IB-DNA complex sitting inside the catalytic site of the enzyme, providing a molecular explanation for the cleavage-inhibition effect. For all these reasons, the aforementioned drug could be a possible lead compound for the development of an efficient anti-tumor molecule targeting human DNA topoisomerase IB.
人类 DNA 拓扑异构酶 IB 通过一个复杂的催化循环来控制超螺旋 DNA 的拓扑状态,该循环由切割和连接反应组成,从而推进基本的 DNA 代谢。在疟疾风险药物基金开放存取药物库中获得的一种药物存在的情况下,分析了人类 DNA 拓扑异构酶 IB 的催化步骤。实验表明,该化合物强烈且不可逆地抑制酶反应的切割步骤,并降低三种不同癌细胞系的细胞活力。分子对接和分子动力学模拟表明,该药物与位于酶催化位点内的人 DNA 拓扑异构酶 IB-DNA 复合物结合,为切割抑制作用提供了分子解释。基于所有这些原因,上述药物可能是开发针对人 DNA 拓扑异构酶 IB 的有效抗肿瘤分子的潜在先导化合物。